Children's Hospital Los Angeles, as part of its current research program on nanoparticle-based therapy for Ewing's sarcoma has signed a research partnership with NanoSmart Pharmaceuticals, a developer of innovative cancer drugs, to develop and validate the novel drug-delivery platform of the company.
Children's Hospital Los Angeles will conduct the partnership research with NanoSmart Pharmaceuticals under the leadership of Timothy Triche, who serves as Director and Professor of Pathology and Pediatrics of the Center for Personalized Medicine of the Children's Hospital Los Angeles Department of Pathology.
NanoSmart is creating a tumor-targeting system using human autoimmune antibodies to target spots of necrosis present in various kinds of cancer. The company intends to create several innovative biopharmaceuticals by mixing the antibodies with a variety of cancer drugs. Its drug-delivery system ensures to enhance the efficiency and safety of current cancer medicines by improving targeting of the tumor spot.
Dr.Triche commented that the collaborative research will support other ongoing research works of the lab. NanoSmart is using naturally available human antibody to direct the nanoparticles towards the tumor site, which if successful will get the quick FDA approval to be used on patients suffered from Ewing's sarcoma, Triche said.
NanoSmart Pharmaceuticals’ President, James Smith stated that through this partnership research, the company can now use the key clinical and preclinical resources. The company will test and classify its formulations in the innovative metastatic Ewing's Sarcoma model at Children's Hospital, he added.
Source: http://www.nanosmartpharma.com